Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y2W3

UPID:
S45A1_HUMAN

ALTERNATIVE NAMES:
Deleted in neuroblastoma 5 protein; Solute carrier family 45 member 1

ALTERNATIVE UPACC:
Q9Y2W3; A0A0A0MT80; Q5VY46; Q5VY49

BACKGROUND:
Proton-associated sugar transporter A, identified by its aliases Deleted in neuroblastoma 5 protein and Solute carrier family 45 member 1, is pivotal in brain glucose transport. Its activity is essential for proper cerebral function and energy balance.

THERAPEUTIC SIGNIFICANCE:
Its association with Intellectual developmental disorder with neuropsychiatric features suggests that targeting Proton-associated sugar transporter A could offer new avenues for treatment. Exploring its function further may reveal innovative approaches to address the cognitive and psychiatric manifestations of this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.